Supplementary Material

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

Tanya Trippett^{1*} · Helen Toledano² · Quentin Campbell-Hewson³ · Arnauld Verschuur⁴ · Anne-Marie Langevin⁵ · Isabelle Aerts⁶ · Lisa Howell⁷ · Soledad Gallego⁸ · Claudia Rossig⁹ · Amy Smith¹⁰ · Darshak Patel^{11†} · Leonardo R. Pereira¹² · Sravanthi Cheeti¹³ · Luna Musib^{13‡} · Katherine E. Hutchinson¹⁴ · Clare Devlin¹⁵ · Ronald Bernardi¹⁶ · Birgit Geoerger¹⁷

¹ Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA

² Schneider Children's Medical Center, Department of Pediatric Hematology-Oncology and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

³ The Great North Children's Hospital, Department of Paediatric and Adolescent Oncology, Newcastle Upon Tyne, UK

⁴ Timone Children's Hospital, Assistance Publique-Hopitaux de Marseille, Pediatric Oncology, Marseille, France

⁵ UT Health San Antonio, Department of Pediatrics, San Antonio, TX, USA

⁶ Institut Curie, PSL Research University, Oncology Center SIREDO, Paris, France

⁷ Alder Hey Children's NHS Foundation Trust, Paediatric Oncology, Liverpool, UK

⁸ Hospital Universitari Vall d'Hebron, Paediatric Oncology, Barcelona, Spain

⁹ University Children's Hospital Muenster, Pediatric Hematology and Oncology, Muenster, Germany

¹⁰ Haley Center for Children's Cancer and Blood Disorders, Orlando-Health Arnold Palmer Hospital for Children, Orlando, FL, USA

¹¹ F. Hoffmann-La Roche Ltd, Product Development, Biometrics, Biostatistics, Mississauga, ON, Canada

¹² Roche Products Ltd, Product Development Safety, Welwyn, UK

¹³Genentech, Inc., Clinical Pharmacology, South San Francisco, CA, USA

¹⁴ Genentech, Inc., Oncology Biomarker Development, South San Francisco, CA, USA

¹⁵ Roche Products Ltd, Product Development Oncology, Welwyn, UK

¹⁶ Genentech, Inc., Product Development Oncology, South San Francisco, CA, USA

 ¹⁷ Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, INSERM U1015, Villejuif, France
 [†]Current affiliation: IQVIA, Mississauga, ON, Canada
 [‡]Current affiliation: Gilead Sciences, Foster City, CA, USA

***Corresponding author:** Tanya Trippett, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY10065, USA. Phone: +1 212-639-8267; E-mail: <u>trippet1@MSKCC.ORG</u>

Definition of Dose-Limiting Toxicities

Dose-limiting toxicities (DLTs) were defined as any of the following events occurring during the DLT assessment window and considered by the investigator to be related or possibly related to cobimetinib:

- Grade \geq 4 neutropenia (absolute neutrophil count [ANC] <0.5 x 10⁹ cells/L) for > 7 days
- Grade ≥ 4 neutropenia with documented infection
- Febrile neutropenia (ANC < 500 cells/mm³ with a single temperature of > 38.3 °C or a sustained temperature of ≥ 38 °C for > 1 h)
- Grade \geq 4 (i.e., life-threatening) anemia of any duration
- Grade ≥ 4 thrombocytopenia for > 48 h or any thrombocytopenia requiring a platelet transfusion, with the following exception: patients who have undergone autologous stem cell transplant or ¹³¹I-metaiodobenzylguanidine therapy, grade ≥ 4 thrombocytopenia for > 7 days or any thrombocytopenia requiring a platelet transfusion on two or more separate dates will be considered a DLT
- Grade ≥ 3 thrombocytopenia with bleeding
- Elevation of serum hepatic transaminase (alanine aminotransferase or aspartate aminotransferase) to ≥ 5 x upper limit of normal (ULN); for patients with elevated hepatic transaminase levels at baseline as a result of liver metastases, hepatic transaminase ≥ 5 x baseline and < 10 x baseline for > 3 days, or any hepatic transaminase ≥ 10 x baseline, will be considered a DLT
- Serum bilirubin elevation to $\ge 3 \times ULN$
- For patients reliably able to report visual symptoms: grade ≥ 2 visual disturbance that does not resolve to grade ≤ 1 within 72 h after interruption of cobimetinib
- Retinal pathology of any grade, or grade ≥ 2 uveitis or iritis
- Grade ≥ 2 hemorrhage of any type
- Intracranial hemorrhage of any grade
- Grade ≥ 4 creatine phosphokinase (CPK) elevation
- Rhabdomyolysis of any grade; rhabdomyolysis includes elevations of CPK in conjunction with either clinical features (such as muscle pain, signs of renal failure, dark red or brown urine) or with laboratory evidence of renal insufficiency (including grade ≥ 2 increased creatinine or creatinine clearance [or radioisotope glomerular filtration rate] < 70 mL/min/1.73 m²), or investigator judgement that a clinical scenario is consistent with rhabdomyolysis
- Grade ≥ 2 ventricular dysfunction or symptomatic congestive heart failure

- Reduction in left ventricular ejection fraction below 50% (or shortening fraction below 28%) AND either symptomatic heart failure or a ≥ 10% relative reduction from baseline measurement. Note: The relative reduction must be ≥ 10% of baseline function, not an absolute decrease of ≥ 10 percentage points
- Grade \geq 4 (i.e., life-threatening) vomiting or diarrhea of any duration
- Grade ≥ 3 non-hematologic, non-hepatic, non-ocular adverse event, with the following exceptions, which will not be considered DLTs: grade ≥ 3 diarrhea or rash that resolves to grade ≤ 2 within 7 days after interruption of cobimetinib; grade 3 fever; grade 3 mucositis or stomatitis that resolves to grade ≤ 2 within 3 days; grade ≥ 3 nausea or vomiting that responds to standard-of-care therapy within 3 days; grade 3 fatigue lasting ≤ 3 days; or grade 3 laboratory abnormalities that are asymptomatic and considered by the investigator not to be clinically significant.

Patients who missed \geq 5 doses, or who discontinued treatment prior to completing the assessment window for reasons other than a DLT, were non-evaluable for dose-escalation and assessment of the maximum tolerated dose and were replaced.

Table S1 Dose	e-limiting toxicities during	dose escalation					
Dose and	Tumor type	Adverse event	Onset	Duration	Most	Action taken	Outcome
formulation					extreme	with study drug	
					NCI CTCAE		
					grade		
1.0 mg/kg	LGG (chiasmatic	Headache	Day 23	12 days	3	Interrupted	Recovered/resolved
tablet	glioma)						
	LGG (optic pathway	Retinal detachment	Day 9	50 days	2	Withdrawn	Recovered/resolved
	glioma)						
0.6 mg/kg	LGG (pilocytic	Chorioretinopathy	Day 13	50 days	1	Interrupted	Recovered/resolved
suspension	astrocytoma)						
1.33 mg/kg	LGG (pilomyxoid	Chorioretinopathy	Day 8	8 days	2	Interrupted	Recovered/resolved
suspension	astrocytoma grade II)		Day 22	_	4	Withdrawn	Not recovered/not resolved
	LGG (optic pathway	Serous retinal	Day 6	7 days	1	Interrupted	Recovered/resolved
	glioma)	detachment					
	Plexiform	Pigment epithelial	Day	_	1	None	Recovering/resolving
	neurofibroma	detachment	111				

LGG low-grade glioma, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events

Patients with events, <i>n</i> (%)	2 - < 6	6 - < 12	12 - < 18	≥ 18	Dose	Dose	Dose
					escalation	escalation	
	years	years	years	years			expansion
	(<i>n</i> = 10)	(<i>n</i> = 31)	(<i>n</i> = 14)	(<i>n</i> = 1)	tablet	suspension	(<i>n</i> = 12)
					(<i>n</i> = 18)	(<i>n</i> = 26)	
AE	10 (100)	31 (100)	14 (100)	1 (100)	18 (100)	26 (100)	12 (100)
Leading to treatment withdrawal	0	2 (7)	4 (29)	0	1 (6)	4 (15)	1 (8)
Leading to dose modification/interruption	3 (30)	11 (36)	4 (29)	1 (100)	4 (22)	12 (46)	3 (25)
Treatment-related AE	9 (90)	28 (90)	12 (86)	1 (100)	16 (89)	23 (89)	11 (92)
Leading to treatment withdrawal	0	2 (7)	4 (29)	0	1 (6)	4 (15)	1 (8)
Leading to dose modification/interruption	1 (10)	6 (19)	4 (29)	1 (100)	3 (17)	8 (31)	1 (8)
SAE	4 (40)	9 (29)	4 (29)	1 (100)	6 (33)	6 (23)	6 (50)
Leading to treatment withdrawal	0	0	1 (7)	0	0	0	1 (8)
Leading to dose modification/interruption	2 (20)	4 (13)	0	1 (100)	1 (6)	3 (12)	3 (25)
Related to study treatment	0	2 (7)	1 (7)	1 (100)	1 (6)	1 (4)	2 (17)
Fatal AE	0	0	0	0	0	0	0
AE of special interest ^a	5 (50)	12 (39)	7 (50)	1 (100)	6 (33)	13 (50)	6 (50)

AE adverse event, SAE serious adverse event

^aSerous retinopathy-related AEs, retinal vein occlusion AEs, rhabdomyolysis, or creatine phosphokinase elevation, rash, potential drug-induced liver injury as defined by Hy's Law, left ventricular dysfunction, any new malignancy including cutaneous squamous cell and basal cell. Multiple occurrences of the same AE in one individual are counted only once, except for the 'AE' row, in which multiple occurrences of the same AE are counted separately.

Tumor type (<i>n</i>)	Test findings (<i>n</i>)	Best confirmed overall response, <i>n</i>				Not evaluable	Not collected
			SD	SD PD	Non-CR/PD	-	
LGG (32)	KIAA1549-BRAF fusion or other tandem duplication of BRAF (15)		12	1	1	1	
	BRAF V600E mutation (1)			1			
	BRAF mutation not specified (1)			1			
	BRAF copy number amplification (1)			1			
	NF1 truncating mutation (1)	1					
	Other mutation in <i>RAS/RAF/MEK/ERK</i> pathway gene not specified (4)		2	2			
	No mutation identified in a <i>RAS/RAF/MEK/ERK</i> pathway gene (5) ^a	1	2	1			1
	Unknown / not provided (4)	1	2				1
HGG (5)	No mutation identified in a RAS/RAF/MEK/ERK pathway gene (1) ^a			1			
	Unknown / not provided (4)			3		1	
NF1-associated neurofibroma	NF1 mutation not specified (3)		3				
(12)	Unknown / not provided (9)		9				
MPNST (2)	Other mutation in <i>RAS/RAF/MEK/ERK</i> pathway gene not specified (1)			1			
	No mutation identified in a RAS/RAF/MEK/ERK pathway gene (1) ^a		1				

ATRT (1)	Other mutation in RAS/RAF/MEK/ERK pathway gene not specified (1)	1	
Metastatic mediastinal yolk sac tumor (1)	RAS mutation (1)		1
Neuroblastoma (1)	Unknown / not provided (1)	1	
Liposarcoma (1)	Unknown / not provided (1)	1	
DNET in Noonan syndrome (1)	Unknown / not provided (1)	1	

ATRT atypical teratoid/rhabdoid tumor, *CR* complete response, *DNET* dysembryoplastic neuroepithelial tumor, *HGG* high-grade glioma, *LGG* low-grade glioma, *MPNST* malignant peripheral nerve sheath tumor, *NF1* neurofibromatosis type 1, *PCR* polymerase chain reaction, *PD* progressive disease, *PR* partial response, *SD* stable disease

^aLack of a noted MAPK pathway gene alteration possibly influenced by type and scope of testing performed at an enrolling site, or due to lack of reporting by site to the Sponsor, as systematic reporting was not required (see Table S4 for additional information).

Tumor type (n)	Test findings (<i>n</i>)	Test type (n)
LGG (32)	KIAA1549-BRAF fusion or other	PCR-based (5)
	tandem duplication of BRAF (15)	FISH (4)
		NGS (3)
		Other test not specified (3
	BRAF V600E mutation (1)	FISH (1)
	BRAF mutation not specified (1)	FISH (1)
	BRAF copy number amplification (1)	Other test not specified (1
	NF1 truncating mutation (1)	Other test not specified (1
	Other mutation in RAS/RAF/MEK/ERK	FISH (1)
	pathway gene not specified (4)	Other test not specified (3
	No mutation identified in a	FISH (2)
	RAS/RAF/MEK/ERK pathway gene (5)	NGS (1)
		Other test not specified (2
	Unknown / not provided (4)	
HGG (5)	No mutation identified in a	Other test not specified (1
	RAS/RAF/MEK/ERK pathway gene (1)	
	Unknown / not provided (4)	
NF1-associated	NF1 mutation not specified (3)	NGS (3)
neurofibroma (12)	Unknown / not provided (9)	
MPNST (2)	Other mutation in RAS/RAF/MEK/ERK	Other test not specified (1
	pathway gene not specified (1)	
	No mutation in RAS/RAF/MEK/ERK	NGS (1)
	pathway genes (1)	
ATRT (1)	Other mutation in RAS/RAF/MEK/ERK	PCR-based (1)
	pathway gene not specified (1)	
Metastatic	RAS mutation (1)	NGS (1)
mediastinal yolk		
sac tumor (1)		
Neuroblastoma (1)	Unknown / not provided (1)	
Liposarcoma (1)	Unknown / not provided (1)	
DNET in Noonan's	Unknown / not provided (1)	
syndrome (1)		

ATRT atypical teratoid/rhabdoid tumor, *DNET* dysembryoplastic neuroepithelial tumor, *FISH* fluorescence in situ hybridization, *HGG* high-grade glioma, *LGG* low-grade glioma, *MPNST* malignant peripheral nerve sheath tumor, *NF1* neurofibromatosis type 1, *NGS* next-generation sequencing, *PCR* polymerase chain reaction





Fig. S1 Comparison of pharmacokinetic profiles between the dose-escalation and expansion cohorts.





LGG low-grade glioma, SPD sum of product diameters, RANO Response Assessment in Neuro-Oncology




Fig. S3 IHC staining for (a) pERK1/2 (n = 3), (b) pMEK1/2 (n = 2 at baseline and/or during study treatment), and (c) Ki67 for evaluable tumor tissue specimens (n = 33).

DNET dysembryoplastic neuroepithelial tumor, *HGG* high-grade glioma, *IHC* immunohistochemistry, *LGG* low-grade glioma, *MAPK* mitogen-activated protein kinase, *MPNST* malignant peripheral nerve sheath tumor, *NRSTS* non-rhabdomyosarcoma soft tissue sarcoma

With the exception of three specimens (one HGG and two MPNST), all baseline Ki67 nuclear expression scores were < 20%. Median percent nuclear Ki67 expression was 10.8% in HGG (n = 4), 2.0% in LGG (n = 23), and 25.3% in MPNST (n = 2).